388 related articles for article (PubMed ID: 22301780)
1. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.
Baumgarten SC; Frasor J
Mol Endocrinol; 2012 Mar; 26(3):360-71. PubMed ID: 22301780
[TBL] [Abstract][Full Text] [Related]
2. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.
Frasor J; Weaver A; Pradhan M; Dai Y; Miller LD; Lin CY; Stanculescu A
Cancer Res; 2009 Dec; 69(23):8918-25. PubMed ID: 19920189
[TBL] [Abstract][Full Text] [Related]
3. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
Smart E; Semina SE; Frasor J
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
[TBL] [Abstract][Full Text] [Related]
4. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.
Pradhan M; Bembinster LA; Baumgarten SC; Frasor J
J Biol Chem; 2010 Oct; 285(41):31100-6. PubMed ID: 20705611
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
6. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
[TBL] [Abstract][Full Text] [Related]
7. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
8. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
10. How to target estrogen receptor-negative breast cancer?
Rochefort H; Glondu M; Sahla ME; Platet N; Garcia M
Endocr Relat Cancer; 2003 Jun; 10(2):261-6. PubMed ID: 12790787
[TBL] [Abstract][Full Text] [Related]
11. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.
Shao W; Brown M
Breast Cancer Res; 2004; 6(1):39-52. PubMed ID: 14680484
[TBL] [Abstract][Full Text] [Related]
12. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
13. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
14. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
15. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Osborne CK; Shou J; Massarweh S; Schiff R
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):865s-70s. PubMed ID: 15701879
[TBL] [Abstract][Full Text] [Related]
18. The changing role of ER in endocrine resistance.
Nardone A; De Angelis C; Trivedi MV; Osborne CK; Schiff R
Breast; 2015 Nov; 24 Suppl 2(0 2):S60-6. PubMed ID: 26271713
[TBL] [Abstract][Full Text] [Related]
19. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
[TBL] [Abstract][Full Text] [Related]
20. New strategies in estrogen receptor-positive breast cancer.
Johnston SR
Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
